ICON plc — FY 2018 Form 20-F
Reporting period: Year ended December 31, 2018. This is an annual report, not a standalone fourth-quarter filing; the provided filing text does not give clear Q4-only financial results. Amounts are in U.S. dollars unless stated otherwise.
Business context
ICON is an Ireland-based global contract research organization providing clinical development, laboratory, consulting, staffing, real-world evidence and related services to pharmaceutical, biotechnology and medical-device companies. At year-end, it had approximately 13,670 employees across 89 locations in 37 countries. It adopted ASC 606 from January 1, 2018, presenting clinical-trial revenue gross, including reimbursable third-party costs; prior-year figures were not restated.
Financial performance and position
| Metric | FY 2018 | FY 2017 |
|---|---|---|
| Revenue as reported | $2,595.8 million | $2,402.3 million |
| Net revenue excluding reimbursables (2018 ASC 606 comparison basis) | $1,892.9 million | Not presented on the same basis |
| Operating income | $373.4 million | $338.3 million |
| Operating margin as reported | 14.4% | 14.1% |
| Net income | $322.7 million | $281.5 million |
| Diluted EPS | $5.89 | $5.13 |
| Cash from operating activities | $268.6 million | $383.1 million |
| Capital expenditures | $48.4 million | $44.7 million |
| Cash and short-term investments | $455.8 million | $360.4 million |
| Working capital | $719.6 million | $535.0 million |
- Reported revenue rose 8.1%; management cited 6.9% growth in constant currency and 3.7% constant-dollar organic growth. Growth reflected organic expansion and Mapi, acquired in July 2017.
- 2018 direct costs were $1,818.2 million, including $702.8 million of reimbursable expenses. Their inclusion under ASC 606 makes direct-cost ratios and reported revenue growth less directly comparable with 2017. SG&A was $325.8 million, or 12.6% of reported revenue.
- The 2018 tax provision was $42.0 million, with an effective tax rate of 11.5%, versus 14.2% in 2017. The filing attributes the rate principally to the geographic distribution of taxable profits.
- Operating cash flow decreased $114.4 million year over year. Management cited higher days’ revenue outstanding (67 days versus 49), extended credit terms for some key accounts, collection timing and lower days’ payment outstanding. Unbilled revenue increased $94.4 million.
- Year-end debt was approximately $349.3 million carrying value ($350 million principal), consisting of fixed-rate senior notes due December 2020; the notes bear 3.64% stated interest. The $150 million revolving facility was undrawn. Cash and investments exceeded debt by approximately $106.5 million.
Material changes and unusual items
- ASC 606 changed the presentation and measurement of clinical-trial services: the company treats the full trial service, including investigator services, as one performance obligation and recognizes revenue over time using project costs. Adoption reduced opening retained earnings by $48.1 million; comparatives were not restated. The filing’s reconciliation indicates FY 2018 net income would have been $326.4 million without ASC 606, versus $322.7 million reported under the new standard.
- Restructuring charges increased to $12.5 million from $7.8 million, including $9.7 million for workforce rationalization and $2.8 million for office consolidation/onerous leases.
- ICON repurchased 1.0 million shares for $129.0 million in 2018. In January 2019 it announced a further opportunistic buyback of up to 1 million shares, subject to cash commitments.
- On January 25, 2019, a subsidiary acquired MolecularMD Corp. for initial consideration of $42 million.
Outlook, risks and contingencies
- No specific revenue or earnings guidance is provided in the filing. Management expects to spend approximately $55 million over the next 12 months on IT, facility expansion and new offices, and believes foreseeable cash needs can be funded through operating cash flow, existing cash and committed facilities.
- Contracted unsatisfied performance obligations were approximately $5.3 billion at year-end. ICON expects about 40% to convert to revenue over the next 12 months, but warns that cancellations, delays and slower conversion mean backlog is not a reliable guarantee of future results.
- Key risks include customer and pharmaceutical-industry concentration, project cancellations and fixed-fee cost overruns, staffing and patient/investigator recruitment, regulatory compliance, data privacy and cybersecurity, foreign-exchange exposure, and competition or customer vendor consolidation. The top five customers generated 39.5% of 2018 revenue; the largest represented 13.6%.
- The company disclosed no litigation expected to have a material adverse effect. It was in compliance with senior-note covenants at year-end. Operating lease commitments totaled $126.6 million; adoption of ASC 842 in 2019 was expected to add $100–$110 million of lease assets and liabilities, with an insignificant net-income effect.
- Brexit terms remained uncertain; management did not expect a significant operational or financial impact at the time of filing. Currency movements remain a risk. ICON reported effective disclosure controls and internal control over financial reporting; KPMG issued unqualified opinions on the financial statements and internal controls.
Important facts for investors to verify
- Use comparable revenue and margin measures that account for the ASC 606 gross presentation and unrevised 2017 comparatives.
- Track receivables, unbilled revenue, days’ revenue outstanding and operating cash conversion, given the 2018 cash-flow decline.
- Assess backlog conversion, project cancellations and customer concentration, rather than treating the $5.3 billion obligation balance as assured revenue.
- Review refinancing or repayment of the $350 million notes due in December 2020, alongside buybacks, planned investment and the MolecularMD acquisition.
- Monitor the estimated ASC 842 balance-sheet impact, restructuring execution, and the use and returns of the additional share repurchase program.